伐地那非增加EGCG-β-乳球蛋白纳米粒对肝癌细胞的抑制作用

较高浓度的EGCG才能抑制癌细胞的增殖,通过纳米化和EGCG与其他药物的联合使用是提高EGCG生物活性的重要策略。本研究将EGCG和伐地那非（VD）同时包埋于β-乳球蛋白（β-Lg）纳米载体中,制备出EGCG-VD-β-Lg纳米粒（EVβ-NPs）,体外试验证实,EVβ-NPs能提高人肝癌细胞（HepG2细胞）中Caspase-3活性,使HepG2细胞在S期产生明显的阻滞,诱发细胞核分裂,从而导致HepG2细胞凋亡。研究结果表明,将EGCG与微量的VD联合使用,并通过纳米化包埋可以显著提高EGCG的抗癌活性。这一方法在EGCG抗癌制品的开发方面具有潜在的价值。

Vardenafil Improves the Proliferative Inhibition of EGCG-β-lactoglobulin Nanoparticles Against Liver Cancer Cells

The combination of nano and other drugs is an important strategy to improve the biological activity of EGCG, since a high EGCG concentration is essential for the inhibition of the proliferation of cancer cells. In this study, EGCG-vardenafil (VD)-β-lactoglobulin (β-Lg)-nanoparticles (EVβ-NPs) was prepared by encapsulating EGCG and VD in β-Lg nano-carriers. In vitro experimental results show that EVβ-NPs could upgrade the activity of caspase-3 in HepG2 cells compared to the native EGCG, which caused cell cycle arrest in the S phase of HepG2 cells to induce cell nuclear division, and finally lead to HepG2 cell apoptosis. The results demonstrate that the encapsulation of EGCG-VD can significantly improve the anticancer activity of EGCG, and possesses potential value in the development of EGCG anticancer products.